Coping After COVID: Dealing with Depression During a Pandemic


Depression is the leading cause of disability in the US.

Even before the pandemic, depression had the ability to touch any demographic across the globe.

The debilitating condition doesn’t discriminate based on race, religion, or socioeconomic situation, costing employers billions in lost wages annually and driving up suicides and other negative outcomes.

That was before COVID-19.

Factor in a pandemic that has reduced social opportunities, while significantly increasing the collective stress of the population, the problem has only grown.

In this month’s episode of Coping After COVID: Navigating Psychiatry After a Pandemic, Steve Levine, MD, Co-Founder and Chairman of Heading Health, spoke on how clinicians can help depression patients mitigate some of the damage caused by the ongoing pandemic.

Levine explained just how damaging depression can be and what happens when a depression patient has to adjust to the different circumstances caused by the pandemic.

And while treatment helps, there is a good chance the already expansive patient pool for depression was expanded drastically because of the events since March 2020.

Levine also said it is important to treat pediatric depression patients differently than adults in terms of both symptom manifestation and how they are treated.

And children may not adjust as well as adults when school becomes remote and social activities become few and far between.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
Bhanu Prakash Kolla, MBBS, MD: Treating Sleep with Psychiatric Illness
How Will Upadacitinib, Povorcitinib Benefit Hidradenitis Suppurativa?
The JAK Inhibitor Safety Conversation
Jonathan Silverberg, MD, PhD, MPH | Credit: George Washington University
© 2024 MJH Life Sciences

All rights reserved.